Literature DB >> 18565592

Antidepressant-associated chronic irritable dysphoria (ACID) in STEP-BD patients.

Rif S El-Mallakh1, S Nassir Ghaemi, Kemal Sagduyu, Michael E Thase, Stephen R Wisniewski, Andrew A Nierenberg, Hong Wei Zhang, Tamara A Pardo, Gary Sachs.   

Abstract

BACKGROUND: It has been proposed that antidepressants can induce a chronic, dysphoric, irritable state in bipolar patients (called ACID for antidepressant-associated chronic irritable dysphoria). This phenomenon has only been described in case series format, and has not been prospectively validated.
METHODS: Prospective data from the first 1500 patients (62.7% with bipolar I, 30.1% with bipolar II, and 7.2% with NOS) treated in the STEP-BD database were examined and those who were euthymic for at least one month at study entry, subsequently developed a depressive episode, and were then followed for one year were identified. Outcome of those who received an antidepressant for this depressive episode (n=27) was compared to those who did not (n=56), with particular attention given to the presence of the proposed symptom triad of ACID, namely dysphoria, irritability, and middle insomnia.
RESULTS: Patients treated with antidepressants were ten times more likely to develop ACID than those who were not (Hazard ratio=9.95, CI=1.103-89.717, P=0.04). However, the hazard ratio dropped to 1.05 (P=0.99) when corrected for significant covariates, notably past antidepressant-related manic switch and sex. DISCUSSION: This study does not support the existence of ACID as an independent phenomenon. Rather, ACID appears to be part of a broader spectrum of antidepressant treatment-emergent affective switches.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18565592     DOI: 10.1016/j.jad.2008.03.025

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  17 in total

Review 1.  Review of evidence for use of antidepressants in bipolar depression.

Authors:  Shane J McInerney; Sidney H Kennedy
Journal:  Prim Care Companion CNS Disord       Date:  2014-10-16

Review 2.  Treatment of Bipolar Disorder in a Lifetime Perspective: Is Lithium Still the Best Choice?

Authors:  Gabriele Sani; Giulio Perugi; Leonardo Tondo
Journal:  Clin Drug Investig       Date:  2017-08       Impact factor: 2.859

Review 3.  The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm.

Authors:  Konstantinos N Fountoulakis; Lakshmi Yatham; Heinz Grunze; Eduard Vieta; Allan Young; Pierre Blier; Siegfried Kasper; Hans Jurgen Moeller
Journal:  Int J Neuropsychopharmacol       Date:  2017-02-01       Impact factor: 5.176

Review 4.  Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry.

Authors:  Konstantinos N Fountoulakis; Siegfried Kasper; Ole Andreassen; Pierre Blier; Ahmed Okasha; Emanuel Severus; Marcio Versiani; Rajiv Tandon; Hans-Jürgen Möller; Eduard Vieta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-06       Impact factor: 5.270

Review 5.  Issues on the diagnosis and etiopathogenesis of mood disorders: reconsidering DSM-5.

Authors:  Kazuyoshi Ogasawara; Yukako Nakamura; Hiroyuki Kimura; Branko Aleksic; Norio Ozaki
Journal:  J Neural Transm (Vienna)       Date:  2017-12-23       Impact factor: 3.575

Review 6.  Translational research in bipolar disorder: emerging insights from genetically based models.

Authors:  G Chen; I D Henter; H K Manji
Journal:  Mol Psychiatry       Date:  2010-02-09       Impact factor: 15.992

Review 7.  The neurobiology of the switch process in bipolar disorder: a review.

Authors:  Giacomo Salvadore; Jorge A Quiroz; Rodrigo Machado-Vieira; Ioline D Henter; Husseini K Manji; Carlos A Zarate
Journal:  J Clin Psychiatry       Date:  2010-05-04       Impact factor: 4.384

8.  A randomized, double-blind, placebo-controlled trial of pregnenolone for bipolar depression.

Authors:  E Sherwood Brown; John Park; Christine E Marx; Linda S Hynan; Claire Gardner; Domingo Davila; Alyson Nakamura; Prabha Sunderajan; Alexander Lo; Traci Holmes
Journal:  Neuropsychopharmacology       Date:  2014-06-11       Impact factor: 7.853

9.  The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders.

Authors:  Isabella Pacchiarotti; David J Bond; Ross J Baldessarini; Willem A Nolen; Heinz Grunze; Rasmus W Licht; Robert M Post; Michael Berk; Guy M Goodwin; Gary S Sachs; Leonardo Tondo; Robert L Findling; Eric A Youngstrom; Mauricio Tohen; Juan Undurraga; Ana González-Pinto; Joseph F Goldberg; Ayşegül Yildiz; Lori L Altshuler; Joseph R Calabrese; Philip B Mitchell; Michael E Thase; Athanasios Koukopoulos; Francesc Colom; Mark A Frye; Gin S Malhi; Konstantinos N Fountoulakis; Gustavo Vázquez; Roy H Perlis; Terence A Ketter; Frederick Cassidy; Hagop Akiskal; Jean-Michel Azorin; Marc Valentí; Diego Hidalgo Mazzei; Beny Lafer; Tadafumi Kato; Lorenzo Mazzarini; Anabel Martínez-Aran; Gordon Parker; Daniel Souery; Ayşegül Ozerdem; Susan L McElroy; Paolo Girardi; Michael Bauer; Lakshmi N Yatham; Carlos A Zarate; Andrew A Nierenberg; Boris Birmaher; Shigenobu Kanba; Rif S El-Mallakh; Alessandro Serretti; Zoltan Rihmer; Allan H Young; Georgios D Kotzalidis; Glenda M MacQueen; Charles L Bowden; S Nassir Ghaemi; Carlos Lopez-Jaramillo; Janusz Rybakowski; Kyooseob Ha; Giulio Perugi; Siegfried Kasper; Jay D Amsterdam; Robert M Hirschfeld; Flávio Kapczinski; Eduard Vieta
Journal:  Am J Psychiatry       Date:  2013-11       Impact factor: 18.112

10.  Asenapine in the Treatment of Bipolar Depression.

Authors:  Rif S El-Mallakh; Sharon Nuss; Dong Gao; Yonglin Gao; Surriya Colleen Ahmad; Clare Schrodt; Caleb Adler
Journal:  Psychopharmacol Bull       Date:  2020-03-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.